Study cohort. A total of 645 participants in the USTMA Consortium iTTP Registry had a confirmed diagnosis with ADAMTS13 deficiency. An exacerbation was counted as a continuation of the iTTP episode that preceded it. We excluded episodes preceded by preemptive therapy (n = 17), patients lost to follow-up, and patients who received therapy other than corticosteroids or rituximab.